Navigation Links
Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
Date:12/15/2010

BRANFORD, Conn., Dec. 15, 2010 /PRNewswire/ -- HistoRx announces that Jack Davis has accepted its invitation to join the Board of Directors.  As the former President and CEO of both a diagnostic product company and a laboratory testing company, he is an acknowledged diagnostic industry expert.

Mr. Davis was Co-founder, President, CEO and eventually Chairman of the Board at Dianon Systems, a leading provider of specialized clinical laboratory and anatomic pathology testing services and disease management systems focusing on cancer, pre-natal genetics and cytogenetics.  Dianon Systems was sold to LabCorp in 2002.  In addition, he served as President and CEO of Calypte Biomedical, a biodiagnostics company that developed the first urine-based HIV test, where he shepherded the company through its IPO.  Previously, he was Division Vice President and worldwide General Manager of Abbott Laboratories Diagnostics Products business unit.

HistoRx CEO Rana K. Gupta approached Mr. Davis with the opportunity, commenting, "Now that HistoRx has proven our license model for diagnostics commercialization, it's crucial to expand our expertise in both the laboratory services business and the diagnostic product arena since these are the avenues of distribution we will continue to pursue.  Jack's experience with running Abbott's worldwide Diagnostics Products business and with building a national anatomic pathology services business at Dianon make him a valuable addition to the HistoRx Board."

"I'm delighted to join the board of directors of HistoRx, a company that, working with the Pathology community at large, is committed to improving the objectivity, reproducibility and quantitation of anatomic pathology," Davis stated. "Testing services based on AQUA technology are improving the quality of care in cancer diagnostics."

About HistoRx (www.historx.com)

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care.  The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis.  AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making.  HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  For more information please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
2. The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine
3. bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
4. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
7. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
8. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
9. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth
11. Life Sciences Company Sword Diagnostics Moves Operations to Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):